SynthesisBMJ (Clinical research ed.)2013
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.
Synthesis in BMJ (Clinical research ed.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06318104 (Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days), which is not on this map. Cited by 100 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days
Who cites it
100 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Perforated and bleeding peptic ulcer: WSES guidelines.World journal of emergency surgery : WJES · 2020Guideline
- Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis.European journal of clinical pharmacology · 2018Pooled it
- ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.The American journal of gastroenterology · 2017Guideline
- Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis.World journal of gastroenterology · 2016Pooled it
- Recurrent aphthous stomatitis and Helicobacter pylori.Medicina oral, patologia oral y cirugia bucal · 2016Pooled it
- Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis.Journal of Korean medical science · 2015Pooled it
- Optimum duration of regimens for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2013Pooled it
- Optimized sequential therapyWorld journal of gastroenterology · 2024Trial
- Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial.BMC infectious diseases · 2023Trial
- Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.Clinical and translational gastroenterology · 2020Trial
- Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment forGut and liver · 2019Trial
- Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Trial
- Trial
- Trial
- Trial
- Trial
- Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial.Gut and liver · 2016Trial
- A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.Medicine · 2016Trial
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo do a systematic review and meta-analysis of studies comparing sequential therapy for eradication of Helicobacter pylori with pre-existing and new therapies, thus providing a glimpse of eradication success worldwide.
designSystematic review and meta-analysis. DATA SOURCES: Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2013; abstract books of major European, American, and Asian gastroenterological meetings. STUDY SELECTION: Randomised controlled trials in previously untreated adults, in which sequential therapy was compared with a pre-existing or new therapy.
results46 randomised controlled trials were reviewed and analysed. 5666 patients were randomised to sequential therapy and 7866 to other (established and new) treatments. The overall eradication rate of sequential therapy was 84.3% (95% confidence interval 82.1% to 86.4%). Sequential therapy was superior to seven day triple therapy (relative risk 1.21, 95% confidence interval 1.17 to 1.25; I(2)=29.3%; number needed to treat 6, 95% confidence interval 5% to 7%), marginally superior to 10 day triple therapy (1.11, 1.04 to 1.19; I(2)= 67.2%; NNT 10, 7 to 15), but not superior to 14 day triple therapy (1.00, 0.94 to 1.06; I(2)=54.3%), bismuth based therapy (1.01, 0.95 to 1.06; I(2)=21.1%), and non-bismuth based therapy (0.99, 0.94 to 1.05; I(2)=52.3%). Data on eradication according to pre-treatment antimicrobial susceptibility testing were available in eight studies, and sequential therapy was able to eradicate 72.8% (61.6% to 82.8%) of the strains resistant to clarithromycin.
conclusionsEradication rates with pre-existing and new therapies for H pylori are suboptimal. Regional monitoring of resistance rates should help to guide treatment, and new agents for treatment need to be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.